![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | C07K 16/28 | (2006.01) |
A61K2039/54 | (2013.01) | ||
A61P 37/06 | (2006.01) | ||
C07K2317/72 | (2013.01) | ||
A61K 39/00 | (2006.01) | ||
A61K2039/505 | (2013.01) | ||
A61K2039/545 | (2013.01) | ||
C07K 16/2803 | (2013.01) | ||
C07K 16/283 | (2013.01) | ||
C07K2317/31 | (2013.01) | ||
C07K2317/76 | (2013.01) | ||
A61P 1/02 | (2018.01) | ||
A61P 1/04 | (2018.01) | ||
A61P 1/16 | (2018.01) | ||
A61P 1/18 | (2018.01) | ||
A61P 11/00 | (2018.01) | ||
A61P 11/02 | (2018.01) | ||
A61P 13/02 | (2018.01) | ||
A61P 13/08 | (2018.01) | ||
A61P 13/12 | (2018.01) | ||
A61P 15/00 | (2018.01) | ||
A61P 17/00 | (2018.01) | ||
A61P 25/00 | (2018.01) | ||
A61P 27/02 | (2018.01) | ||
A61P 29/00 | (2018.01) | ||
A61P 35/00 | (2018.01) | ||
A61P 37/02 | (2018.01) | ||
A61P 37/06 | (2018.01) | ||
A61P 43/00 | (2018.01) | ||
A61P 5/06 | (2018.01) | ||
A61P 5/10 | (2018.01) | ||
A61P 7/00 | (2018.01) | ||
A61P 9/00 | (2018.01) |
(11) | Number of the document | 3468997 |
(13) | Kind of document | T |
(96) | European patent application number | 17731411.9 |
Date of filing the European patent application | 2017-06-08 | |
(97) | Date of publication of the European application | 2019-04-17 |
(45) | Date of publication and mention of the grant of the patent | 2023-09-13 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2017/036635 |
Date | 2017-06-08 |
(87) | Number | WO 2017/214452 |
Date | 2017-12-14 |
(30) | Number | Date | Country code |
201662347419 P | 2016-06-08 | US | |
201662399896 P | 2016-09-26 | US | |
201662421261 P | 2016-11-12 | US |
(72) |
ZACK, Debra , US
STONE, John H. , US
PILLAI, Shiv , US
FOSTER, Paul , US
|
(73) |
Xencor, Inc. ,
465 North Halstead Street
Suite 200, Pasadena, CA 91107,
US
|
(54) | TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B |
TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B |